The Medicines Co. recently released update information regarding its ORION-1 clinical trial, which revolves around PCSK9si, the company’s investigational PCSK9 synthesis inhibitor. Read More »
Pfizer has released data from its Phase 1b INLYTA clinical trial in which the drug is combined with pembrolizumab, a PD-1 inhibitor called KEYTRUDA, and marketed by Merck. Read More »
The U.S. Food and Drug Administration has sent Nicox S.A. a Complete Response Letter in regard to its AC-170 New Drug Application. Read More »
Hepatitis C medication costs in 2015 proved lower for the U.S. than Europe and Japan, particularly prices negotiated by pharmacy benefit managers in Medicare Part D, the Pharmaceutical Care Management Association recently reported. Read More »
Pharmacy benefit managers (PBMs) are proven in helping the control rising prescription drug prices and should be part of the solutions adopted by policymakers, writes Pharmaceutical Care Management Association (PCMA) President Mark Merritt in an op-ed published yesterday in The Hill. Read More »
Medicaid could see $51.1 billion over the next decade if a “full range of pharmacy benefit management tools” is employed, according to a new report completed by The Menges Group and released by the Pharmaceutical Care Management Association (PCMA). Read More »
UnitedHealth Group this week released its third quarter results, reporting that the company has experienced growth at a well-balanced level and steady execution in all areas of its various businesses. Read More »
Corvus Pharmaceuticals has released its biomarker findings in its ongoing Phase 1/1b clinical trial involving CPI-444, as both a single agent and as a combination with TECENTRIQ, a Genentech product that is a fully humanized monoclonal antibody developed to target cell death ligand 1 protein. Read More »
Lundbeck's Carnexiv injection -- an orally administered replacement therapy for short-term use to treat adults with specific types of seizures -- has been approved by the U.S. Food and Drug Administration. Read More »
CymaBay Therapeutics has received a patent to treat NAFLD and NASH with MBX-0825 by administering an amount that proves to be therapeutically effective orally. Read More »
The U.S. Food and Drug Administration has accepted KenPharm's Investigational New Drug application for KP415, the company’s extended release d-threomethylphenidate prodrug that was developed to treat attention deficit hyperactivity disorder. Read More »
Supernus Pharmaceuticals' Phase IIb clinical trial involving SPN-812 to determine dosing ranges has turned in positive topline results for the treatment of attention deficit hyperactivity disorder (ADHD) in children. Read More »
Vernalis Therapeutics Inc. has initiated its promotion of MOXATAG Tablets to primary care physicians in the United States. Read More »
Sen. Kelly Ayotte (R-NH) has been honored for her work in driving a bill through Congress aimed at battling the opioid, heroin and fentanyl abuse epidemic. Read More »
Pfizer has released results from its Phase 3 S-TRAC clinical study involving the assessment of SUTENT as an adjuvant therapy. Read More »
Pfizer has released data from its Phase 1b clinical trial involving INLYTA, which has been combined with pembrolizumab, a PD-1 checkpoint inhibitor known as KEYTRUDA, in patients who have advanced renal cell carcinoma (RCC) that have yet to undergo treatment. Read More »
ACADIA Pharmaceuticals has been named the recipient of the 2016 Pantheon DiNA Award by the California Life Sciences Association for its therapeutic product NUPLAZID. Read More »
Walgreens customers shopping in stores in the southeast United States can make donations to the American Red Cross Relief Fund to help the victims of Hurricane Matthew. Read More »
Napo Pharmaceuticals has launched Mytesi, the only medication approved by the U.S. Food and Drug Administration for the relief of diarrhea in patients who have HIV. Read More »
At first, price-slashing discount coupons for expensive drugs may appeal to consumers on an everyday basis, but a look behind the scenes suggests that using brand-name medications may possibly yield little, if any, net savings. Read More »
Alerts Sign-up